Zim Laboratories Approves FY2026 Financials, Appoints Cost Auditor
Zim Laboratories Limited announced the outcome of its Board Meeting held on May 19, 2026. The Board considered and approved the Audited Financial Statements (Standalone and Consolidated) for the year ended March 31, 2026, along with the Financial Results for the quarter and year ended March 31, 2026.During the meeting, the company also appointed M/s Dhananjay V. Joshi & Associates, Cost Accountants, as the Cost Auditor for the Financial Year 2026-27.
The statutory auditors, Deloitte Haskins & Sells LLP, issued an auditor's report confirming an unmodified opinion on the financial results for the year ended March 31, 2026.
Financial Review and Annual Reports
The company released comprehensive financial statements, including the Balance Sheets, Cash Flow Statements, and results tables, for both consolidated and standalone entities, covering the years ended March 31, 2026, and March 31, 2025.Consolidated Financial Results (Lakhs)
The Statement of Consolidated Financial Results provided a comparison of key financial metrics:| Particulars | 31 March 2026 (Audited) | 31 March 2025 (Audited) |
|---|---|---|
| Total Income | 38,578.31 | 38,481.51 |
| Total Expenses | 37,757.03 | 36,680.57 |
| Profit after tax | 583.81 | 1,216.50 |
| Total comprehensive income attributable to Owners | 794.48 | 1,213.77 |
| Total Assets | 53,938.71 | 47,227.43 |
| Total Equity and Liabilities | 53,938.71 | 47,227.43 |
Standalone Financial Results (Lakhs)
The Standalone Statement of Financial Results showed the following key figures:| Particulars | 31 March 2026 (Audited) | 31 March 2025 (Audited) |
|---|---|---|
| Total Income | 38,187.14 | 38,125.64 |
| Total Expenses | 37,347.12 | 36,364.43 |
| Profit after tax | 596.52 | 1,174.40 |
| Total comprehensive income | 586.70 | 1,120.56 |
| Total Assets | 52,519.97 | 46,438.52 |
| Total Equity and Liabilities | 52,519.97 | 46,438.52 |
Balance Sheet Summary (Lakhs)
The audited Balance Sheet data shows significant increases in total assets and equity for the company between the two fiscal years.| Category | As at 31 March 2026 | As at 31 March 2025 |
|---|---|---|
| TOTAL ASSETS | 53,938.71 | 47,227.43 |
| Property, plant and equipment (Non-current) | 15,643.23 | 15,834.39 |
| Inventories (Current) | 9,377.48 | 8,647.00 |
| Trade receivables (Current) | 10,903.80 | 10,692.03 |
| Cash and cash equivalents (Current) | 2,512.19 | 194.66 |
| TOTAL EQUITY AND LIABILITIES | 53,938.71 | 47,227.43 |
The Cash Flow Statement reported a Net cash from operating activities of 4,953.41 lakhs for the year ended March 31, 2026, compared to 4,115.46 lakhs in the previous year.
These financial statements, along with the auditor's reports, were reviewed and approved by the Audit Committee and the Board of Directors.
ZIMLAB Stock Price Movement
Today, Zim Laboratories Limited shares rallied, closing at ₹100.6 after gaining 4.71%. The equity saw a robust trading volume of 45,544 shares today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.